



MannKind to Present at the 13th Annual BIO CEO & Investor Conference

02/08/11

MannKind to Present at the 13th Annual BIO CEO & Investor Conference

VALENCIA, Calif., Feb 08, 2011 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 13th Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011 at 11:00 AM (ET) at the Waldorf Astoria in New York, New York.

Interested parties can access a link to the live webcast of the presentation from the News & Media section of the Company's website at www.mannkindcorp.com.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA[®] and MKC253. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MKC253 is currently in phase 1 clinical trials. Other products in MannKind's pipeline include the cancer immunotherapy platform MKC1106, which is currently in phase 2 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com